GX-188E DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trialResearch in context

GX-188E DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trialResearch in context

Summary: Background: In an interim analysis of this phase 2 trial, adding the GX-188E vaccine to pembrolizumab resulted in manageable toxicity with antitumor activities in patients with recurrent or advanced cervical cancer. Here, we report the final safety and efficacy results after a long-term fo...

Full description

Bibliographic Details
Main Authors: Myong Cheol Lim, Youn Jin Choi, Soo-Young Hur, Yong-Man Kim, Jae Hong No, Byoung-Gie Kim, Chi Heum Cho, Sung Hoon Kim, Dae Hoon Jeong, Jae-Kwan Lee, Ji Hyun Kim, Yoon-Jeong Choi, Jung Won Woo, Young Chul Sung, Jong Sup Park
Format: Article
Language:English
Published: Elsevier 2024-08-01
Series:EClinicalMedicine
Subjects:
Cervical cancer
DNA vaccine
HPV
Pembrolizumab
Overall survival
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024002955

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024002955

Similar Items